Kelly N. Fitzgerald , Chung-Han Lee , Martin H. Voss , Maria I. Carlo , Andrea Knezevic , Laura Peralta , Yingbei Chen , Robert A. Lefkowitz , Neil J. Shah , Colette N. Owens , Deaglan J. McHugh , David H. Aggen , Andrew L. Laccetti , Ritesh R. Kotecha , Darren R. Feldman , Robert J. Motzer
{"title":"Cabozantinib加Nivolumab治疗非透明细胞肾细胞癌患者:II期试验的最新结果》更正 [Eur. Urol. 86(2) (2024) 90-94]","authors":"Kelly N. Fitzgerald , Chung-Han Lee , Martin H. Voss , Maria I. Carlo , Andrea Knezevic , Laura Peralta , Yingbei Chen , Robert A. Lefkowitz , Neil J. Shah , Colette N. Owens , Deaglan J. McHugh , David H. Aggen , Andrew L. Laccetti , Ritesh R. Kotecha , Darren R. Feldman , Robert J. Motzer","doi":"10.1016/j.eururo.2024.10.002","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 1","pages":"Page 96"},"PeriodicalIF":25.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94]\",\"authors\":\"Kelly N. Fitzgerald , Chung-Han Lee , Martin H. Voss , Maria I. Carlo , Andrea Knezevic , Laura Peralta , Yingbei Chen , Robert A. Lefkowitz , Neil J. Shah , Colette N. Owens , Deaglan J. McHugh , David H. Aggen , Andrew L. Laccetti , Ritesh R. Kotecha , Darren R. Feldman , Robert J. Motzer\",\"doi\":\"10.1016/j.eururo.2024.10.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12223,\"journal\":{\"name\":\"European urology\",\"volume\":\"87 1\",\"pages\":\"Page 96\"},\"PeriodicalIF\":25.3000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0302283824026435\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0302283824026435","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
作者感到遗憾的是,文中对不良事件(AE)发生率的估计值有四处错误,与相应表格中的正确估计值不符。具体而言,文中对以下治疗相关不良事件发生率的估计值有误:1)任何级别的不良事件;2)3-4 级不良事件;3)3-4 级 AST 事件;4)3-4 级 ALT 事件。正确值已列入相应的补充表 2 和表 4,并在此予以说明:40名患者(100%)发生了任何级别的治疗相关不良反应;20名患者(50%)发生了3-4级不良反应。治疗相关的 3-4 级 AST 和 ALT 升高分别为 13% 和 15%。
Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94]
期刊介绍:
European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.